NextCure, Inc.
NXTCNASDAQHealthcare● Active
$2.79
$-0.16(-5.42%)
Market Cap$7476469
P/E Ratio—
52W High$15.74
52W Low$2.65
NextCure, Inc. (NXTC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NXTC · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.87
Est. -$1.81 · -3.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
NXTC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$1.91 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$1.81 | -$1.87 | -3.3% | — | — | — |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$2.26 | -$0.81 | +64.2% | — | — | — |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$4.06 | -$3.22 | +20.7% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$4.62 | -$11.29 | -144.4% | — | — | — |
| ▲ Q2 FY2025 | May 1, 2025 | -$4.80 | -$4.68 | +2.5% | — | — | — |
| ▼ Q1 FY2025 | Mar 6, 2025 | -$4.08 | -$4.92 | -20.6% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$4.20 | -$4.92 | -17.1% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$1.91
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$1.87
EPS Est.
-$1.81
EPS Surpr.
-3.3%
Revenue
—
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
-$0.81
EPS Est.
-$2.26
EPS Surpr.
+64.2%
Revenue
—
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$3.22
EPS Est.
-$4.06
EPS Surpr.
+20.7%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$11.29
EPS Est.
-$4.62
EPS Surpr.
-144.4%
Revenue
—
Q2 FY2025
May 1, 2025Beat
EPS Actual
-$4.68
EPS Est.
-$4.80
EPS Surpr.
+2.5%
Revenue
—
Q1 FY2025
Mar 6, 2025Miss
EPS Actual
-$4.92
EPS Est.
-$4.08
EPS Surpr.
-20.6%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$4.92
EPS Est.
-$4.20
EPS Surpr.
-17.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-2.69 | $-2.69 | $-2.69 | 1 |
| Q3 FY2027 | $-2.51 | $-2.51 | $-2.51 | 1 |
| Q2 FY2027 | $-2.37 | $-2.37 | $-2.37 | 1 |
| Q1 FY2027 | $-2.20 | $-2.20 | $-2.20 | 1 |
| Q4 FY2026 | $-1.86 | $-1.86 | $-1.86 | 1 |
| Q3 FY2026 | $-1.78 | $-1.78 | $-1.78 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -3.3% | $10.72 | $10.18 | -5.04% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +64.2% | $12.60 | $12.76 | +1.27% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +20.7% | $9.64 | $9.63 | -0.10% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -144.4% | $5.16 | $5.10 | -1.16% |
| ▲ Q2 FY2025 | May 1, 2025 | +2.5% | $5.58 | $5.76 | +3.23% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -20.6% | $8.88 | $8.55 | -3.72% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -17.1% | $15.72 | $15.84 | +0.76% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -52.8% | $19.44 | $19.32 | -0.62% |
Q2 FY2026-5.04%
Report Date
May 7, 2026
EPS Beat/Miss
-3.3%
Price Before
$10.72
Price After
$10.18
Q1 FY2026+1.27%
Report Date
Mar 5, 2026
EPS Beat/Miss
+64.2%
Price Before
$12.60
Price After
$12.76
Q4 FY2025-0.10%
Report Date
Nov 5, 2025
EPS Beat/Miss
+20.7%
Price Before
$9.64
Price After
$9.63
Q3 FY2025-1.16%
Report Date
Aug 7, 2025
EPS Beat/Miss
-144.4%
Price Before
$5.16
Price After
$5.10
Q2 FY2025+3.23%
Report Date
May 1, 2025
EPS Beat/Miss
+2.5%
Price Before
$5.58
Price After
$5.76
Q1 FY2025-3.72%
Report Date
Mar 6, 2025
EPS Beat/Miss
-20.6%
Price Before
$8.88
Price After
$8.55
Q4 FY2024+0.76%
Report Date
Nov 7, 2024
EPS Beat/Miss
-17.1%
Price Before
$15.72
Price After
$15.84
Q3 FY2024-0.62%
Report Date
Aug 1, 2024
EPS Beat/Miss
-52.8%
Price Before
$19.44
Price After
$19.32
Avg Beat Reaction+1.47%
Avg Miss Reaction-1.96%
Beat Rate3 / 8 quarters
Largest Move-5.04% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NXTC ends December
NextCure, Inc. (NXTC) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.87 — missing the analyst consensus of $-1.81 by -3.3%. The next NXTC earnings date is expected around September 1, 2026.
Each quarter, investors track NXTC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NXTC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NXTC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NXTC earnings · 5 questionsNextCure, Inc.'s next earnings report is expected around September 1, 2026. NXTC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NXTC historically reports after market close (AMC).
NXTC earnings datewhen is NXTC earningsNXTC next earnings datewhen does NXTC report earningsNXTC earnings calendar
▸ Source: FMP · NextCure, Inc. SEC filings · US GAAP · NextCure, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026